Results Snapshot
Quarterly Analysis Highlights - YoY
Net Sales
YoY Growth in quarter ended Jun 2025 is 40.25% vs -6.48% in Jun 2024
Consolidate Net Profit
YoY Growth in quarter ended Jun 2025 is 697.06% vs -114.11% in Jun 2024
Operating Profit (PBDIT) excl Other Income
YoY Growth in quarter ended Jun 2025 is 366.67% vs -75.18% in Jun 2024
Interest
YoY Growth in quarter ended Jun 2025 is 2.78% vs 140.00% in Jun 2024
Operating Profit Margin (Excl OI)
YoY Growth in quarter ended Jun 2025 has improved from Jun 2024
Compare Quarterly Results Of Chengdu Olymvax Biopharmaceuticals, Inc. With
Quarterly - Net Sales
QoQ Growth in quarter ended Jun 2025 is 148.74% vs -56.65% in Mar 2025
YoY Growth in quarter ended Jun 2025 is 40.25% vs -6.48% in Jun 2024
Quarterly - Consolidate Net Profit
QoQ Growth in quarter ended Jun 2025 is 390.00% vs -144.30% in Mar 2025
YoY Growth in quarter ended Jun 2025 is 697.06% vs -114.11% in Jun 2024
Quarterly - Operating Profit (PBDIT)
QoQ Growth in quarter ended Jun 2025 is 1,300.00% vs -90.73% in Mar 2025
YoY Growth in quarter ended Jun 2025 is 366.67% vs -75.18% in Jun 2024
Quarterly - Interest
QoQ Growth in quarter ended Jun 2025 is 0.00% vs -5.13% in Mar 2025
YoY Growth in quarter ended Jun 2025 is 2.78% vs 140.00% in Jun 2024
Quarterly - Operating Profit Margin (Excl OI)
QoQ Growth in quarter ended Jun 2025 has improved from Mar 2025
YoY Growth in quarter ended Jun 2025 has improved from Jun 2024






